Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA), has approved the company’s nine presentations of heparin sodium injection, USP.Heparin is a vital anticoagulant, preventing the formation of clots and extension of existing clots within the blood, routinely used in surgical and dialysis settings. According to IMS, 2009 US sales of all forms of un-fractionated heparin approximated $306 million. Sagent will launch the product immediately..................................& more
No comments:
Post a Comment